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Introduction: Spinal cord stimulation (SCS) is recommended for the treatment of postsurgical 
chronic back and leg pain refractory to other treatments. We wanted to estimate the incidence 
and predictive factors of SCS treatment in our lumbar surgery cohort.
Patients and methods: Three questionnaires (a self-made questionnaire, the Oswestry Low 
Back Pain Disability Questionnaire, and the Beck Depression Inventory) were sent to patients 
aged 18–65 years with no contraindications for the use of SCS, and who had undergone non-
traumatic lumbar spine surgery in the Oulu University Hospital between June 2005 and May 
2008. Patients who had a daily pain intensity of ≥5/10 with predominant radicular component 
were interviewed by telephone.
Results: After exclusions, 814 patients remained in this cohort. Of those, 21 patients had received 
SCS by the end of June 2015. Fifteen (71%) of these received benefit and continued with the 
treatment. Complications were rare. The number of patients who replied to the postal survey were 
537 (66%). Eleven of them had undergone SCS treatment after their reply. Features predicting 
SCS implantation were daily or continuous pain, higher intensities of pain with predominant 
radicular pain, more severe pain-related functional disability, a higher prevalence of depressive 
symptoms, and reduced benefit from pain medication. The mean waiting time was 65 months 
(26–93 months). One hundred patients were interviewed by telephone. Fourteen seemed to be 
potential SCS candidates. From the eleven patients who underwent SCS after responding to 
the survey, two were classified as potential candidates in the phone interview, while nine were 
other patients. Twelve patients are still waiting for treatment to commence. 
Conclusion: In our region, the SCS treatment is used only for very serious pain conditions. Waiting 
time is too long and it may be the reason why this treatment option is not offered to all candidates.
Keywords: disc surgery, spinal fusion, decompression surgery, chronic back and leg pain, Beck 
Depression Inventory, Oswestry Disability Index
Introduction
Spinal cord stimulation (SCS) has been used for five decades to treat certain states of 
chronic pain refractory to other treatments. SCS is mainly used for chronic peripheral 
neuropathic pain (eg, radicular pain due to spine diseases or peripheral nerve trauma), 
but it has also been recommended for complex regional pain syndrome and certain 
types of ischemic vascular disease (refractory angina pectoris and severe peripheral 
limb ischemia).1,2 The most common condition for SCS is postsurgical chronic back 
and leg pain (CBLP), formerly called failed back surgery syndrome, referring to cases 
with continuing pain after adequate lumbar surgical procedure.3 For patients with 
CBLP, SCS has been reported to be superior to conservative medical management4 or 
reoperation5 in randomized studies. 
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According to the International Neuromodulation Society, 
about 34,000 patients undergo spinal cord stimulator implants 
each year around the world.6 SCS is shown to be cost-effective 
in the management of neuropathic or ischemic pain states.7
In SCS, an electrode is placed in the posterior epidural 
space at the level where electrical stimulation from the device 
produces a tingling sensation called paresthesia in the painful 
area and reduces pain by replacing the painful sensation.8 
Test stimulations are administered over a period of few days 
using an external pulse generator to ensure sufficient response 
before implanting a permanent device under the skin.2
The mechanisms involved in pain-relieving effect of SCS 
are still not fully understood. According to the “gate control” 
theory, elective stimulation of the large-diameter afferent 
fibers (Aβ) blocks the central transmission of small fibers 
(Aδ, C) and abolishes painful inputs. According to animal 
models, SCS seems to release many substances including 
substance P, glycin, gamma-aminobutyric acid, and serotonin, 
which are known to be involved with pain modulation in 
the spinal cord. It has been suggested that SCS may abolish 
peripheral ischemic pain by inhibiting sympathetic activity, 
reducing vasoconstriction, and releasing vasoactive agents 
from sensory fibers to cause vasodilatation.3
SCS is an invasive treatment which carries the risk of 
adverse events. Patients occasionally experience device com-
plications, such as a displaced lead, an internally fractured 
electrode, or device malfunction. Major complications are, 
however, rare.9 The most common medical problems are 
bleeding at the implant site or infection. The latter usually 
necessitates removal of the device and antibiotic treatment. 
Persistent pain at the lead anchor site and implantable pulse 
generator pocket are important in 20% of patients, and up to 
5% of patients require a pocket revision in order to achieve 
better comfort.6 According to a recent systematic review, 
adverse events in patients treated by SCS due to chronic low 
back pain conditions mostly included lead migration (13.2%), 
lead breakage (9.1%), and other minor hardware problems. 
The overall infection rate was 3.4%.10
We have previously reported the outcome of lumbar spine 
surgery in the Oulu University Hospital (OUH) based on a 
postal survey targeted at working-aged patients operated 
between 2005 and 2008.11–13 In this article, we have esti-
mated the incidence of SCS in this cohort and sought factors 
predicting the use of SCS as a treatment option. We further 
evaluated a group of patients who predominantly had leg 
pain (ie, potential candidates for SCS) applying international 
criteria for SCS.14
Patients and methods
OUH is the main center of spinal surgery and the only one 
implanting SCS in Northern Finland. OUH provides special-
ist care for a population of 730,000. Lumbar spine surgery 
patients during the period June 1, 2005 to May 31, 2008 were 
identified using ICD-10 procedure codes. Acute traumas were 
excluded. Only working-aged patients (18–65 years) were 
included. Each patient was listed only once, and the index 
operation was defined as the latest lumbar spine surgery 
during the above mentioned period. Exclusion criteria were 
insufficient capacity in the Finnish language, major abuse 
problem, or progressive, severe illness (eg, cancer, dementia, 
organ failure). The ICD-10 diagnosis code for spinal disease 
and previous lumbar spine operations before the index sur-
gery were recorded. The study protocol was approved by the 
Regional Ethics Committee of the Northern Ostrobothnia 
Hospital District, and the patients gave their written informed 
consent to participate in the study.
The questionnaires and a consent form were sent to all 
traceable patients in September 2009. The patients were asked 
to fill in three questionnaires: 1) a self-made questionnaire, 
2) the Oswestry Low Back Pain Disability Questionnaire, and 
3) the Beck Depression Inventory (BDI). The self-made ques-
tionnaire included questions regarding the occurrence of pain 
(never, occasionally, daily or almost daily, and all the time), 
the average intensity of pain (numeric rating scale [NRS], 
0–10), and pain-associated disability (NRS 0–10). Axial 
low back pain and radicular pain were assessed separately. 
Self-reported weight and height were used to calculate body 
mass index. Relevant clinical data, including information on 
the trial and implantation of SCS, were updated from patient 
records until the end of June 2015.
Patients were selected through telephone interview as 
potential SCS candidates based on data from the self-made 
questionnaire. The patients interviewed by telephone were 
those who had daily pain intensity of ≥5/10 and whose 
radicular pain component was more dominant than axial low 
back pain. Surgical, medical, and other treatments and their 
outcomes, general health condition, and working capacity 
were thoroughly discussed during the telephone interview. 
After this interview, the researcher (MV or VJ) judged 
whether the patient was a suitable candidate for SCS or not. 
Judgment criteria for SCS were daily pain intensity ≥5/10 
with a duration ≥6 months despite appropriate noninvasive 
treatments, a dominant radicular pain component, no psy-
chosocial contraindications for SCS (eg, abuse problems, 
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Factors of spinal cord stimulation
 litigation process), no medical contraindications due to ill-
nesses or their medication (eg, anticoagulants), no indications 
for new lumbar surgery, and the patient’s own motivation for 
SCS treatment.
Statistical analysis 
Descriptive statistics include means and SDs for continu-
ous variables and numbers and percentages for categorical 
variables. Statistical comparison between the groups was 
performed by two-sample t-test or bootstrap type t-test, chi-
square test, or Fisher–Freeman–Halton test when appropri-
ate. The bootstrap method is significantly helpful when the 
theoretical distribution of the test statistic is unknown or in 
the case of a violation of the assumptions. The SCS incidence 
rates (per 1000 person-years) with 95% CI were calculated 
assuming a Poisson distribution. Crude and standardized 
estimates of SCS incidence were calculated by using Poisson 
regression models. The normality of variables was evaluated 
by the  Shapiro–Wilk W test. Correlation coefficients were cal-
culated by the Pearson method. All analyses were performed 
using STATA 14.1 (StataCorp LP, College Station, TX, USA). 
P-values <0.05 were considered significant.
Results
Figure 1 provides information on the study population. 
During the follow-up (from June 1, 2005 to June 30, 2015) 
21 patients out of 809 had an SCS implanted. Those who 
underwent SCS implantation were compared to those who 
did not receive an SCS device. The demographic data and 
clinical characteristics of the patients are presented in Table 1. 
There were no significant differences between the groups. 
In the entire lumbar spine surgery cohort (respondents 
and non-respondents, n=809), a total of 6741 person-years 
were followed up in 459 men and 350 women. During the 
follow-up (median 8.4 years [IQR 7.7–9.2]), 21 patients 
(3.0% [95% CI: 0.7–4.8]) underwent SCS implantation. 
Figure 1 Flowchart of the lumbar surgery patients included in the study.
Note: *Not included in the analyses.









814 were mailed postal
survey in September 2009
427 did not meet
criteria for phone
interview





14 potential SCS candidates
(of them 2 had received
SCS after the postal survey)





   273 aged ≥ 65 years
   43 with severe illness
   28 reoperated during follow-up
   7 with abuse problem
   4 with insufficient understanding of
Finnish
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The total incidence of SCS was 3.12 per 1000 person-years 
(95% CI: 2.03–4.78). The corresponding numbers for women 
and men were 3.75 (95% CI: 2.08–6.78) and 2.62 (95% CI: 
1.41–4.88), respectively. The age- and diagnose-adjusted 
incidence rate was 1.33 (95% CI: 0.55–3.22). 
The success of SCS treatment was evaluated using 
patient records of these 21 SCS patients. Three stimulators 
were removed after the trial period and three shortly (2–8 
months) after implantation. Fifteen out of 21 (71%) patients 
received benefit from and continued to use the SCS. Eight 
patients have continued or returned to work, whereas seven 
have retired. Two patients were reported to gain excellent 
pain relief from the SCS and were able to discontinue all 
pain medication. Modifications in pain medication were not 
routinely documented. No hematomas or infections were 
reported. One patient suffered a post-spinal headache after 
implantation of the SCS and required a prolonged hospital 
stay. Five patients needed lead revisions, three of whom 
needed it twice. One SCS device was completely replaced. 
Two long-term stimulators were removed because of the need 
for MRI. Two patients died during the follow-up, the causes 
of death were without relation to SCS.
Altogether 537 patients responded to the postal survey, 
and 11 of them had an SCS implanted after the postal 
survey. Their results were compared to those respondents 
who did not receive an SCS (Table 2). Features of pain that 
predicted SCS implantation were daily or continuous pain, 
higher pain intensity (NRS) both in axial low back pain and 
radicular pain, and radicular pain intensity higher than axial 
low back pain. SCS patients had more pain-related disabil-
ity according to both self-reported NRS and the Oswestry 
questionnaire. Their mean Oswestry Disability Index (ODI) 
value reflected severe functional disability compared to a 
moderate functional disability in those without SCS. Their 
mean Beck depression score was higher, reflecting moderate 
depression compared to normal values for those without SCS. 
According to the self-reported NRS, those with SCS received 
significantly less benefit from medication. The mean waiting 
time for SCS implantation was 65 months (26–93 months) 
from the index operation.
There were 110 respondents whose pain profiles fulfilled 
the criterion for phone interview. According to patient 
records, four of them were operated on after the index 
operation, two had passed away, and four already had an 
SCS when answering the survey. One hundred patients were 
interviewed.
After the thorough phone interview, 14 of the 100 patients 
appeared to be potential SCS candidates. Eleven patients 
received the SCS after they had responded to the survey. 
Two of these were classified as “potential SCS candidates” 
based on the phone interview and nine were other patients 
(Table 3). There was a strong positive correlation between 
BDI and ODI in the phone-interviewed group (Figure 2).






Number of female, n (%) 339 (43) 11 (52) 0.39
Age, mean (SD) 44 (11) 40 (9) 0.10
Diagnose, n (%) 0.080
M51.1a 566 (72) 13 (62)
M51.3b 25 (3) 3 (14)
M48.0c 129 (16) 3 (14)
M43.1d 30 (4) 0 (0)
M96e 38 (5) 2 (10)
Type of surgery, n (%) 0.34
Disc surgery 549 (69) 12 (57)
Stabilizing surgery 124 (16) 4 (19)
Decompression 115 (15) 5 (24)
Notes: aLumbar and other intervertebral disc disorders with radiculopathy, bother 
specified intervertebral disc degeneration, cspinal stenosis, dspondylolisthesis, 
epostsurgical musculoskeletal disorders without specific classification.
Abbreviation: SCS, spinal cord stimulation.
Table 2 Predictive factors for SCS implantation and comparison 
of respondents with or without SCS implanted during the follow-








Number of female, n (%) 238 (45) 5 (45) 0.99
Age, mean (SD) 45 (11) 43 (8) 0.39
Body Mass Index, mean (SD) 27.3 (4.8) 28.9 (6.1) 0.31
Index operation first, n (%) 459 (87) 9 (82) 0.64
Type of surgery, n (%) 0.52
Disc surgery 355 (68) 6 (55)
Stabilizing surgery 83 (16) 2 (18)
Decompression 87 (17) 3 (27)
Occurrence of pain, n (%) <0.001
None 40 (8) 0 (0)
Occasionally 191 (37) 0 (0)
Daily 243 (47) 4 (36)
All the time 46 (9) 7 (64)
Pain intensity (NRS), mean (SD)
Axial low back pain 4.2 (2.3) 5.8 (2.3) 0.031
Radicular pain 3.7 (2.7) 6.3 (1.6) 0.002
Disability (NRS), mean (SD) 4.9 (2.7) 7.4 (1.6) 0.003
Oswestry Disability Index, mean (SD) 24 (18) 49 (9) <0.001
Beck Depression Index Score, 
mean (SD)
9.2 (8.7) 22.1 (10) <0.001
Beck Depression Index Score ≥10 201 (38) 10 (91) <0.001
Response to pain medication, 
(NRS 0–10), mean (SD)
6.2 (2.3) 4.0 (1.4) 0.004
Note: Two patients already had SCS at the time of the questionnaire and their 
results were excluded from this comparison.
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Factors of spinal cord stimulation
Discussion
The main findings of this study were a relatively low inci-
dence of SCS for surgically operated CBLP patients, targeted 
to the most difficult pain conditions with a good outcome 
and few complications. Features of the pain that predicted 
SCS implantation were daily or continuous pain and higher 
intensities in both axial and radicular pain. SCS patients 
also had more severe levels of functional disability and more 
moderate depressive symptoms and benefited less from pain 
medication. According to our results, patient selection was 
compatible with international criterion,14 but patient selec-
tion was rather strict.
The mean waiting time for SCS in our hospital was 
65 months, which is about the same as that reported in a 
retrospective analysis of 437 SCS patients in Canada.15 The 
cumulative incidence of SCS was constant for up to 9 years. 
It has previously been confirmed that the long-term success 
rate of SCS is inversely proportional to the time interval 
between the beginning of the chronic pain syndrome and 
the implantation time. The efficacy of SCS exceeds 85% 
if implantation occurs within 2 years of symptom onset.16 
Very few patients received SCS within 2 years of their index 
operation in our region. 
It would appear that SCS as a treatment option does 
not cover all potential candidates in our region. Eleven 
respondents had SCS implanted during the follow-up 
time. Two of these had also been classified as potential 
candidates during the telephone interview. Nine patients 
who had SCS implanted were either non-respondents or did 
not otherwise fulfill our criteria for the telephone interview 
at the time of the survey. In addition, the telephone inter-
view revealed 12 new potential candidates for trial. Our 
study was cross-sectional, and patients’ pain status may 
have changed after they had answered the postal survey. 
It should also be kept in mind that final decision as to the 
applicability of an SCS trial period cannot be based on the 
telephone interview alone. 
The study period of this report was 2005–2015. In 2008 
the National Institute for Health and Care Excellence (NICE) 
published a technology appraisal guidance on SCS. This 
guidance recommends SCS as a cost-effective treatment 
for patients with neuropathic pain.17 In 2009, a systematic 
review on SCS came to a cautiously optimistic conclusion 
in our national Finnish Medical Journal: careful patient 
selection, avoidance of delays in treatment initiation, broad 
experience, and good expertise in both spinal nerve stimu-
lation and other treatment options are important factors in 
obtaining the most effective treatment for neuropathic pain 
patients.18 Vyawahare et al19 assessed the impact of the NICE 
guidance by comparing SCS uptake in England pre-NICE 
and post-NICE. Despite the positive recommendation for the 
routine use of SCS, there was no increase in SCS uptake.19 
This same tendency can be seen in our study: the incidence 
is constant throughout the years in this population, despite 
national and international recommendations. 
It can be observed that the decision regarding the com-
mencement of SCS treatment has been made without repeated 
operations, as there was no difference in re-operations 
between SCS patients and others. North et al5 compared 
SCS to repeated lumbosacral spine surgery in a prospective 
randomized controlled trial. They confirmed that SCS was 
more effective than reoperation as a treatment for persistent 
radicular pain after lumbosacral spine surgery. In the majority 
of cases it obviated the need for reoperation.5 
Table 3 Number of potential SCS candidates according to the 
phone interview compared to number of implanted SCSs
SCS candidate SCS implanted
No Yes Total
No 514 9 523
Yes 12 2 14
Total 526 11 537
Abbreviation: SCS, spinal cord stimulation.
Figure 2 Relationship between BDI and ODI in the group interviewed by telephone. 
Note: Gray area represents 95% confidence intervals.

























r=0.68 (95% CI: 0.63 – 0.72)
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SCS treatment is expensive, and in Finland, it is mainly 
offered to working-aged patients, which lead to age-limitation 
in our study. Of 15 long-term users, eight were able to return 
to work using SCS treatment along with other treatments. 
The role of SCS in the rehabilitation of these individuals 
cannot be ascertained from the results of this retrospective 
study alone. One could claim, however, that patient selec-
tion has been appropriate and that the cost-benefit analysis 
of these SCS treatments is positive in those cases. In health 
economics studies, the cost of an SCS system has been esti-
mated to pay for itself within 3–4 years when compared to 
usual care. Patients who benefit have fewer medical visits, 
reduced pain medication use, improved quality of life, better 
sleep quality, greater activity levels, and may be more likely 
to return to work.6
This study examines the use of traditional SCS in lumbar 
surgery patients. The outcome of this treatment has been 
improved through continuous research and technological 
advancements in the field of neuromodulation. Traditional 
SCS (using a frequency range from 1 to 200 Hz) requires 
that the paresthesia covers the area of pain to be effective. 
New techniques are showing promise in conditions that have 
not responded well to traditional SCS. High-frequency SCS 
involving stimulation rates of 10,000 Hz produces better pain 
relief without paresthesia.20 Dorsal root ganglion stimula-
tion has been shown to be effective in conditions (such as 
CRPS) or locations (such as the inguinal region and foot) 
that have been challenging to treat with traditional SCS.21 
New potential indications for stimulation are undergoing 
pilot studies, for example, in cluster headache or irritable 
bowel syndrome.22,23
There were several limitations in this study. Although 
the initial number of lumbar surgery patients was high, the 
number of SCS patients was low, and this somewhat impairs 
the comparison. The success of the SCS treatment was 
evaluated via patient records. Documentation was largely 
operation-orientated, and possible changes in pain profile, 
medication, functional disabilities, quality of life, and/or 
mood disturbances were not systematically documented. 
Conclusion
It would appear that SCS treatment is used only for the 
treatment of very serious pain conditions in our region. 
This treatment option is not known well enough throughout 
the treatment pathway of the patients, and may possibly not 
be offered to all potential candidates. A regional strategy is 
necessary to reach these patients in time. 
Disclosure
The authors report no conflicts of interest in this work. 
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